marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Lixte Biotechnology Holdings Financial Ratios 2011-2024 | LIXT
Annual Financial Ratios Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.9 | -0.2 | -2.4 | -10.5 | -20.6 | -24.8 | -4.0 | -2.7 | -3.8 | -2.6 | -2.1 | -12.6 | -8.5 |
P/S |
- | - | - | - | - | - | - | - | 53.8 | - | - | - | - |
EPS |
-2.7 | -4.0 | -0.5 | -0.3 | -0.2 | -0.0 | -0.0 | -0.0 | -0.1 | -0.1 | -0.0 | -0.1 | -0.1 |
EV (Enterprise Value) |
203 K | -4.04 M | 11.2 M | 29.5 M | 47.9 M | 48.9 M | 6.32 M | 5.76 M | 11 M | 7.33 M | 2.76 M | 24.6 M | 17.9 M |
EBITDA per Share |
-2.66 | -3.99 | -0.5 | - | -0.0357 | -0.0362 | -0.0324 | -0.0446 | -0.0609 | -0.0623 | -0.0331 | -0.0531 | -0.0531 |
EV/EBITDA |
-1.3 | - | -19.9 | -22.9 | -3.3 | -2.6 | -3.8 | -2.6 | -1.8 | -13.0 | -9.4 | ||
PEG |
- | 0.02 | 62.3 | 2.07 | -0.15 | -0.1 | -1.75 | 0.03 | -0.05 | -6.29 | -0.13 | ||
P/B |
1.0 | 0.2 | 3.1 | 6.9 | 20.7 | 12.8 | 7.3 | 26.8 | 34.5 | 26.7 | 12.3 | 17.4 | 222.5 |
P/CF |
-1.0 | -0.3 | -3.9 | -16.1 | -30.0 | -35.0 | -5.1 | -3.4 | -4.9 | -4.3 | -2.5 | -21.5 | -12.9 |
ROE % |
-127.34 | -122.21 | -140.46 | -65.14 | -100.25 | -51.70 | -181.74 | -994.01 | -913.16 | -1040.46 | -581.90 | -138.62 | -2616.98 |
ROA % |
-118.07 | -113.51 | -132.10 | -62.44 | -91.33 | -49.19 | -132.19 | -492.54 | -476.96 | -512.92 | -245.51 | -118.17 | -480.92 |
ROCE % |
-127.42 | -122.19 | -140.29 | -65.17 | -102.30 | -51.82 | -181.88 | -994.10 | -847.29 | -876.08 | -572.85 | -125.39 | -2335.31 |
Current Ratio |
- | - | - | 24.1 | 11.2 | 20.6 | 3.7 | 2.0 | 2.1 | 2.0 | 1.8 | 6.7 | 1.2 |
DSO |
- | - | - | - | - | - | - | - | 365.0 | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Lixte Biotechnology Holdings
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.44 | -0.45 | - | -0.49 | -1 | -0.08 | - | -0.89 | -0.95 | -0.12 | - | -0.09 | -0.13 | -0.14 | - | -0.14 | -0.03 | -0.03 | - | -0.02 | -0.01 | -0.01 | - | -0.02 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.02 | -0.01 | -0.02 | - | -0.01 | -0.02 | -0.02 | - | -0.01 | -0.01 | -0.01 | - | -0.05 | -0.02 | -0.02 | - | -0.02 | -0.01 | -0.01 |
EBITDA per Share |
- | - | - | - | - | - | - | -0.89 | -0.95 | -0.12 | - | -0.09 | -0.13 | -0.14 | - | -0.14 | -0.03 | -0.03 | - | -0.02 | -0.01 | -0.01 | - | -0.02 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.02 | -0.01 | -0.02 | - | -0.01 | -0.01 | -0.02 | - | -0.01 | -0.01 | -0.01 | - | -0.02 | -0.01 | -0.02 | - | -0.01 | -0.01 | -0.01 |
ROE % |
-158.53 | -148.36 | -116.17 | -139.22 | -141.58 | -100.26 | -91.40 | -111.79 | -109.13 | -113.73 | -68.22 | -100.17 | -111.74 | -93.94 | -47.05 | -91.38 | -103.75 | -121.39 | -87.02 | -112.08 | -92.81 | -76.74 | -43.25 | -89.73 | -111.14 | -131.56 | -138.27 | -439.50 | -694.27 | -923.27 | -753.62 | -1003.25 | -951.65 | -853.52 | -716.63 | -905.22 | -844.17 | -962.72 | -816.79 | -949.29 | -893.20 | -770.46 | -870.50 | -1110.43 | -1217.86 | -1301.68 | -719.78 | -3336.76 | -5713.81 | -8090.87 | -7850.94 | -2616.98 | -2616.98 | -2616.98 |
ROA % |
-134.96 | -130.72 | -104.94 | -126.62 | -128.83 | -94.20 | -81.18 | -100.74 | -98.63 | -103.29 | -65.38 | -96.01 | -107.09 | -90.29 | -45.10 | -85.48 | -95.23 | -110.94 | -79.28 | -103.12 | -86.58 | -72.29 | -41.15 | -74.95 | -84.91 | -97.75 | -100.57 | -249.83 | -365.30 | -471.95 | -373.43 | -503.82 | -484.94 | -440.61 | -374.31 | -467.28 | -429.86 | -483.60 | -402.66 | -458.76 | -421.88 | -350.51 | -368.56 | -572.74 | -720.83 | -858.92 | -612.55 | -1093.73 | -1370.73 | -1647.73 | -1443.55 | -481.18 | -481.18 | -481.18 |
ROCE % |
-158.47 | -148.56 | -116.40 | -139.46 | -141.72 | -100.33 | -91.33 | -111.70 | -109.02 | -113.62 | -68.17 | -100.12 | -111.71 | -93.92 | -47.13 | -92.03 | -104.98 | -123.32 | -88.72 | -113.79 | -93.96 | -77.18 | -43.29 | -89.84 | -111.32 | -131.75 | -136.55 | -437.86 | -692.61 | -921.60 | -753.70 | -1003.34 | -951.68 | -853.55 | -650.77 | -839.37 | -778.33 | -812.59 | -652.40 | -784.90 | -728.80 | -690.33 | -429.94 | -486.12 | -409.81 | -280.52 | -122.67 | -754.45 | -1330.05 | -1743.36 | -1516.17 | -631.78 | -440.12 | -444.26 |
Current Ratio |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.0 | - | - | - | - | - | - | - | 2.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | 8.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | -8.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency